Below are the most recently updated broker updates which include ratings and price targets for Anika Therapeutics Inc. (NASDAQ:ANIK).

04/27/2016 – Broker: Northland Securities Rating: market perform downgrade

02/26/2016 – Broker: Barrington Research Rating: outperform New Target: 49 reiteration

08/27/2015 – Broker: First Analysis Rating: equal weight newcoverage

11/12/2014 – Broker: Singular Research Rating: buy New Target: 45.5 reiteration

05/28/2014 – Broker: ING Rating: buy New Target: 54 reiteration

02/26/2014 – Broker: Summer Street Rating: buy New Target: 60 reiteration

11/04/2013 – Broker: Thomson Reuters/Verus Rating: hold downgrade

The average price target from the most recent broker reports is 52.12

The stock increased +0.02% (+0.01) during the last days session, reaching 44.03 and roughly 202285 shares were bought or sold by traders.

View other investors thoughts on Anika Therapeutics Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.